Masitinib is commercialized in Europe under the brand name Masivet® for the treatment of dogs with non-resectable mast cell tumours (Grade 2 or 3) with a confirmed mutated c-kit tyrosine kinase receptor.
Mast cell tumours (MCTs) are the most common cutaneous malignancies in dogs.
Masivet® is an effective, well-tolerated and proven treatment for dog MCT and was the first tyrosine kinase inhibitor registered in veterinary oncology when it was approved by the European Medicine Agency in 2008.
AB Science celebrated in 2018 the 10th anniversary of the marketing authorization of Masivet®.
The Summary of Product Characteristics is available here.
Medical information and Pharmacovigilance
For any medical inquiry regarding Masivet and notification of adverse event or incident, please contact us by phone at the following number : +33 6 77 57 19 25.
You can also notify any adverse event directly to Competent Authority according to local regulations. In France, you can notify directly via the website https://pharmacovigilance-anmv.anses.fr.
AB Science makes sure to provide the most-up-to-date information regarding its products.